Trials / Unknown
UnknownNCT04436406
PD-L1 Expression in Cancer (PECan Study).
Measurement of PD-L1 Expression in Cancer to Monitor Treatment Response.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study. To determine the baseline level and variability within and between patients and tumour types of PD-L1 expression in melanoma and non-small cell lung cancer in immunotherapy naïve patients using \[99mTc\]-anti-PD-L1 SPECT/CT and immunohistochemistry.
Detailed description
Using \[99mTc\]-labeled anti-PD-L1 single-domain antibody, this study aims to prospectively measure changes in PD-L1 expression determined with SPECT/CT imaging and correlate these changes with response to anti-PD(L)1 immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | [99mTc]-NM-01 SPECT/CT | Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT |
Timeline
- Start date
- 2020-03-11
- Primary completion
- 2023-10-31
- Completion
- 2024-01-31
- First posted
- 2020-06-18
- Last updated
- 2022-12-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04436406. Inclusion in this directory is not an endorsement.